Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of its ImmunoCard STAT!® product line with the addition of ImmunoCard STAT! FLU A&B. The ImmunoCard STAT! FLU A&B product is CLIA waived and meets the new FDA reclassification requirements. ImmunoCard STAT! FLU A&B detects the presence of influenza A & B in nasal and […]
Meridian Bioscience Elects John Rice to the Board of Directors
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Board of Directors elected a new independent director, John M. Rice, Ph.D., effective August 8, 2017. Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests […]